WallStreetZenWallStreetZen

NASDAQ: MREO
Mereo Biopharma Group PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for MREO

Based on 2 analysts offering 12 month price targets for Mereo Biopharma Group PLC.
Min Forecast
$6.00+115.83%
Avg Forecast
$6.50+133.81%
Max Forecast
$7.00+151.8%

Should I buy or sell MREO stock?

Based on 2 analysts offering ratings for Mereo Biopharma Group PLC.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MREO stock forecasts and price targets.

MREO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-10
lockedlocked$00.00+00.00%2024-03-28

1 of 1

Forecast return on equity

Is MREO forecast to generate an efficient return?
Company
N/A
Industry
10.16%
Market
29.75%

Forecast return on assets

Is MREO forecast to generate an efficient return on assets?
Company
N/A
Industry
9.1%

MREO revenue forecast

What is MREO's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$110.0M+999.9%
Avg 2 year Forecast
$50.0M+400%
MREO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MREO revenue growth forecast

How is MREO forecast to perform vs Biotechnology companies and vs the US market?
Company
999.9%
Industry
246.82%
Market
13.23%
MREO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MREO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MREO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MREO$2.78$6.50+133.81%Strong Buy
REPL$6.33$37.67+495.06%Strong Buy
NGNE$30.23$43.00+42.24%Strong Buy
BMEA$10.77$55.80+418.11%Buy
LXRX$1.60N/AN/A
View Top Biotech Stocks

Mereo Biopharma Group Stock Forecast FAQ

Is Mereo Biopharma Group Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: MREO) stock is to Strong Buy MREO stock.

Out of 2 analysts, 1 (50%) are recommending MREO as a Strong Buy, 1 (50%) are recommending MREO as a Buy, 0 (0%) are recommending MREO as a Hold, 0 (0%) are recommending MREO as a Sell, and 0 (0%) are recommending MREO as a Strong Sell.

If you're new to stock investing, here's how to buy Mereo Biopharma Group stock.

What is MREO's revenue growth forecast for 2024-2025?

(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of 999.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 246.82%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.23%.

Mereo Biopharma Group's revenue in 2024 is $10,000,000.On average, 1 Wall Street analysts forecast MREO's revenue for 2024 to be $77,134,560,320, with the lowest MREO revenue forecast at $77,134,560,320, and the highest MREO revenue forecast at $77,134,560,320.

In 2025, MREO is forecast to generate $35,064,351,450 in revenue, with the lowest revenue forecast at $35,064,351,450 and the highest revenue forecast at $35,064,351,450.

What is MREO's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: MREO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 9.1%.

What is MREO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year MREO price target, the average MREO price target is $6.50, with the highest MREO stock price forecast at $7.00 and the lowest MREO stock price forecast at $6.00.

On average, Wall Street analysts predict that Mereo Biopharma Group's share price could reach $6.50 by Apr 10, 2025. The average Mereo Biopharma Group stock price prediction forecasts a potential upside of 133.81% from the current MREO share price of $2.78.

What is MREO's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: MREO) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.